Global Pharmaceutical Contract Development and Manufacturing Market

Pharmaceutical Contract Development and Manufacturing Market Size, Share, Growth Analysis, By Service(Pharmaceutical Manufacture, Drug Development, And Biologics Manufacturing.), By End user(Large pharmaceutical firms, small & mid-size pharmaceutical companies, and generic pharmaceutical companies.), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35J2034 | Region: Global | Published Date: July, 2024
Pages: 242 | Tables: 63 | Figures: 75

Pharmaceutical Contract Development and Manufacturing Market Regional Insights

The pharmaceutical contract development and manufacturing market is anticipated to be dominated by North America in 2022, followed by Europe and Asia-Pacific. The substantial share of this region is primarily linked to expanding generic medicine and biologics demand, CDMO consolidation, rising need for biosimilars due to patent expiry, and rising outsourcing costs. Furthermore, the focus on pharmaceutical and biotechnology research by organisations has made the contract manufacturing business in North America extremely competitive.

However, during the forecast period, Asia-Pacific is expected to have the greatest CAGR. With a revenue share of more than 40%, Asia Pacific dominated the market and is anticipated to expand significantly over the forecast period. This expansion is made possible by an increase in the number of businesses outsourcing work to these nations' emerging economies. Due to their growing production capacities, nations like Singapore, China, and India have recently been recognised as key players in the pharmaceutical sector. The Asian businesses' plenty of cash is to blame for the contract manufacturing industry's monopolistic nature. Significant investments from Asian CMOs are anticipated to spur exponential growth. Due to the presence of well-established multinational players in this area, the Latin American market is predicted to grow significantly over the course of the forecast period. Novartis, Roche, and Pfizer are three significant companies with operations in Brazil. Latin America has the potential to emerge into a major global centre for the creation of pharmaceutical goods. This shift is the result of several factors, including the cheap cost of product creation.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 122.25 Billion in 2023 and is poised to grow from USD 130.69 Billion in 2024 to USD 238.25 Billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

To improve their market position, players in the industry are concentrating on agreements, partnerships, collaborations, acquisitions, and other tactics. Pharma firms must provide more and better new pharmaceuticals to combat the diseases to which the human body is susceptible in order to combat the rising number of new diseases. 'Catalent', 'Patheon', ' Lonza Group AG   ', ' Thermo Fisher Scientific, Inc.   ', ' Boehringer Ingelheim GmbH   ', ' Evonik Industries AG   ', ' Recipharm AB   ', ' Vetter Pharma International GmbH   ', ' WuXi AppTec Co. Ltd.   ', ' Famar Health Care Services   ', ' Almac Group   ', ' Jubilant Life Sciences Limited   ', ' Samsung BioLogics   ', ' PRA Health Sciences   ', ' Cambrex Corporation   ', ' Ajinomoto Bio-Pharma Services   ', ' Syneos Health   ', ' Mylan N.V.   ', ' AMRI Global   ', ' Baxter BioPharma Solutions '

The market is being driven by the advantages of outsourcing, namely the savings in time and money. To increase their share of outsourcing revenue, market players frequently spend on infrastructure, staff, and technology.

With the rise in cancer incidence and the creation of safe and efficient medications thanks to technical advancements, the market for oncology treatments has expanded quickly. Because of the growing demand for potent, focused medicines and the ability of compounds to be more selective towards the target of interest to reduce dosing frequencies, there is an increasing interest in highly potent New Chemical Entities (NCEs).

The pharmaceutical contract development and manufacturing market is anticipated to be dominated by North America in 2022, followed by Europe and Asia-Pacific. The substantial share of this region is primarily linked to expanding generic medicine and biologics demand, CDMO consolidation, rising need for biosimilars due to patent expiry, and rising outsourcing costs. Furthermore, the focus on pharmaceutical and biotechnology research by organisations has made the contract manufacturing business in North America extremely competitive.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Pharmaceutical Contract Development and Manufacturing Market

Report ID: SQMIG35J2034

$5,300
BUY NOW GET FREE SAMPLE